EpicentRx Closes $35 million Series D Financing to Support Development of Small Molecule Immunotherapy and Oncolytic Viral Platform

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2qO4XDc
via IFTTT